% | $
Quotes you view appear here for quick access.

Aegerion Pharmaceuticals, Inc. (AEGR) Message Board

  • chesaresus chesaresus Jun 10, 2013 8:42 AM Flag


    Interview by prof. Nordestgaard, leading expert in hyperlipidemias

    Commenting on the study for heartwire, Dr Børge Nordestgaard (University of Copenhagen, Denmark) stressed that this particular group of patients "have such severe disease and until very lately, typically died very young."

    The two drugs recently approved for this group represent "breakthroughs" he said, but "neither of these are without side effects.

    "So there's really a need for other drugs, because I'm sure there will be lots of patients, even with these two products, who won't tolerate them or won't tolerate them long term." That said, the LDL reductions seen in the TESLA trial with PCSK9 were not as great as those seen in the trials of these other agents, Nordestgaard noted.

    "But now, for the first time, we have some drugs that mean these patients have a chance to live longer and not die as teenagers or in their 20s. That's really something."

    Stein's talk estimated that HoFH affects approximately one in a million people, but Nordestgaard said population-screening studies suggest the number is higher, perhaps as high as one in 40 000.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • 1 in 40,000? You must be part of the conspiracy, as is this Nordestgaard person. Has anybody checked Wikipedia on this matter? We simply must tell all these patients that they are not allowed to have this disease because it conflicts with the Wikipedia 2003 article that pulls from the 1973 data.

2.21+0.02(+0.91%)Oct 21 4:00 PMEDT